stockrow
Saturday 7 November 2026
Export ADTX’s income statement to Excel — free account
Aditxt, Inc.
ADTX Healthcare Biotechnology
Aditxt, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3,200.00, down 97.6% from fiscal 2024.
- Revenue
- +1,120.0%
- EPS
- +99.6%
- Free cash flow
- +60.8%
Quarter to March 2026, against a year earlier
0.00
0.00
NaN
Follow ADTX
Alert me
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
37.33 | 303.30 | 622.36 | 222.34 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.12) | (0.10) | (1.57) | (1.13) | |
P/B ratio |
0.00 | 0.24 | 0.00 | 0.22 | |
Price to Tangible BV |
0.00 | 0.24 | 0.00 | 0.22 | |
EV/Sales |
110.59 | (303.83) | 817.87 | 304.39 | |
EV/EBITDA |
0.00 | 0.05 | 0.00 | 0.00 | |
EV/Operating CF |
(0.09) | 0.04 | (0.21) | (0.16) | |
EV/FCF |
(0.09) | 0.04 | (0.21) | (0.16) | |
Quick Ratio |
0.02 | 0.26 | 0.02 | 0.02 | |
Current Ratio |
0.06 | 0.31 | 0.02 | 0.02 | |
Net Debt/EBITDA |
0.06 | 0.70 | 0.06 | 0.07 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.29 | 1.52 | 0.10 | 0.33 | |
Capex/Depreciation |
(0.14) | (0.12) | 0.00 | 0.00 | |
Interest Coverage |
(160.96) | (15.58) | (17.79) | (129.80) | |
Research and Development Expense of Revenue |
8,582.79% | 137,150.00% | 96,000.00% | 76,430.00% | |
Selling, General and Administrative Expense of Revenue |
27,193.44% | 1,030,250.00% | 352,657.14% | 538,810.00% | |
Intangible Assets out of Total Assets |
0.04 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 47,330.00% | |
Graham Net Nets |
(90.34) | (9.30) | (5.51) | (7.53) | |
Graham Number |
89,581.07 | 0.00 | 0.00 | 31,543,586.64 | |
Earnings Yield |
(774,954.52%) | (223,877.17%) | 5,444,520.49% | 1,016,150.52% | |
Free Cash Flow Yield |
(3,481.47%) | (2,734.58%) | (615.59%) | (840.95%) | |
Revenue per Share |
0.60 | 0.08 | 3.50 | 11.61 | |
Operating CF per Share |
(226.67) | (1,772.47) | (11,723.00) | (27,693.65) | |
Capex per Share |
(0.51) | (2.63) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(227.18) | (1,775.09) | (11,723.00) | (27,693.65) | |
Cash per Share |
13.31 | 613.19 | 815.00 | 3,759.15 | |
Shareholders Equity per Share |
(1,741.31) | 757.95 | (44,296.00) | 139,297.41 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1,741.31) | 757.95 | (44,296.00) | 139,297.41 | |
Free Cash Flow |
(4.59) | (9.26) | (2.34) | (2.38) | |
Working Capital |
(12.49) | (8.40) | (20.24) | (20.15) | |
Capital Expenditures |
(0.01) | (0.01) | — | — | |
Net Current Asset Value |
(48.23) | (8.74) | (20.24) | (20.26) | |
EV/EBIT |
0.00 | 0.05 | 0.00 | 0.00 | |
Capex to Sales |
0.85 | 34.25 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.58 | — | 0.71 | 0.22 | |
Average Payables |
7.63 | 10.45 | 13.07 | 11.90 | |
Average Inventory |
0.07 | 0.01 | 0.05 | 0.29 | |
Average Assets |
22.56 | 24.33 | 20.82 | 30.53 | |
Average Common Equity |
(9.71) | 2.52 | (2.21) | 9.17 |
Columns are period end dates · fundamentals updated 26 Oct 2026